Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deferred Tax Liability: 2019-2024

Historic Non-Current Deferred Tax Liability for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $2.4 million.

  • Revolution Medicines' Non-Current Deferred Tax Liability fell 24.46% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 24.46%. This contributed to the annual value of $2.4 million for FY2024, which is 24.46% down from last year.
  • Latest data reveals that Revolution Medicines reported Non-Current Deferred Tax Liability of $2.4 million as of FY2024, which was down 24.46% from $3.1 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Non-Current Deferred Tax Liability peaked at $7.4 million during FY2020, and registered a low of $2.4 million during FY2024.
  • In the last 3 years, Revolution Medicines' Non-Current Deferred Tax Liability had a median value of $3.1 million in 2023 and averaged $4.2 million.
  • Data for Revolution Medicines' Non-Current Deferred Tax Liability shows a maximum YoY crashed of 55.66% (in 2023) over the last 5 years.
  • Revolution Medicines' Non-Current Deferred Tax Liability (Yearly) stood at $7.4 million in 2020, then remained steady at $7.4 million in 2021, then decreased by 5.63% to $7.0 million in 2022, then plummeted by 55.66% to $3.1 million in 2023, then decreased by 24.46% to $2.4 million in 2024.